Noxopharm Ltd's (ASX:NOX) Dr Graham Kelly speaks to Proactive's Andrew Scott from the ASX Small and Mid-Cap Conference. Noxopharm is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock. Veyonda® is its first pipe-line drug candidate currently in Phase 2 clinical trialling.
Noxopharm with Proactive at the ASX Small and Mid-Cap Conference
